The Generic Drug User Fees Amendment III (GDUFA III) program administered by the FDA Office of Generic Drugs has many promises in the making to approve quality generic drugs for the American public. The GDUFA III program, which commenced in October ’22, has improved communication with the agency to increase both ANDA approval numbers and to help complex generic drugs to enter the market.
read more